Switch theme
Sign up to access all valuation multiples
Jiangsu Nhwa Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in manufacturing of APIs and dosages.
2007
1.6K+
LTM Revenue $817M
LTM EBITDA $202M
$2.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jiangsu Nhwa has a last 12-month revenue of $817M and a last 12-month EBITDA of $202M.
In the most recent fiscal year, Jiangsu Nhwa achieved revenue of $785M and an EBITDA of $204M.
Jiangsu Nhwa expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiangsu Nhwa valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $695M | $785M | XXX | XXX | XXX |
| Gross Profit | $452M | $506M | XXX | XXX | XXX |
| Gross Margin | 65% | 64% | XXX | XXX | XXX |
| EBITDA | $184M | $204M | XXX | XXX | XXX |
| EBITDA Margin | 27% | 26% | XXX | XXX | XXX |
| Net Profit | $124M | $143M | XXX | XXX | XXX |
| Net Margin | 18% | 18% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Jiangsu Nhwa's stock price is CNY 22 (or $3).
Jiangsu Nhwa has current market cap of CNY 22.3B (or $3.1B), and EV of CNY 18.6B (or $2.6B).
See Jiangsu Nhwa trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.6B | $3.1B | XXX | XXX | XXX | XXX | $0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Jiangsu Nhwa has market cap of $3.1B and EV of $2.6B.
Jiangsu Nhwa's trades at 3.1x LTM EV/Revenue multiple, and 12.7x LTM EBITDA.
Analysts estimate Jiangsu Nhwa's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Jiangsu Nhwa and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.6B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 12.5x | XXX | XXX | XXX |
| P/E | 19.5x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 39.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJiangsu Nhwa's NTM/LTM revenue growth is 14%
Jiangsu Nhwa's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Jiangsu Nhwa's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Jiangsu Nhwa's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Jiangsu Nhwa and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 40% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 50% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangsu Nhwa acquired XXX companies to date.
Last acquisition by Jiangsu Nhwa was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiangsu Nhwa acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Jiangsu Nhwa founded? | Jiangsu Nhwa was founded in 2007. |
| Where is Jiangsu Nhwa headquartered? | Jiangsu Nhwa is headquartered in China. |
| How many employees does Jiangsu Nhwa have? | As of today, Jiangsu Nhwa has 1.6K+ employees. |
| Is Jiangsu Nhwa publicy listed? | Yes, Jiangsu Nhwa is a public company listed on SHE. |
| What is the stock symbol of Jiangsu Nhwa? | Jiangsu Nhwa trades under 002262 ticker. |
| When did Jiangsu Nhwa go public? | Jiangsu Nhwa went public in 2008. |
| Who are competitors of Jiangsu Nhwa? | Similar companies to Jiangsu Nhwa include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Jiangsu Nhwa? | Jiangsu Nhwa's current market cap is $3.1B |
| What is the current revenue of Jiangsu Nhwa? | Jiangsu Nhwa's last 12-month revenue is $817M. |
| What is the current EBITDA of Jiangsu Nhwa? | Jiangsu Nhwa's last 12-month EBITDA is $202M. |
| What is the current EV/Revenue multiple of Jiangsu Nhwa? | Current revenue multiple of Jiangsu Nhwa is 3.1x. |
| What is the current EV/EBITDA multiple of Jiangsu Nhwa? | Current EBITDA multiple of Jiangsu Nhwa is 12.7x. |
| What is the current revenue growth of Jiangsu Nhwa? | Jiangsu Nhwa revenue growth between 2023 and 2024 was 13%. |
| Is Jiangsu Nhwa profitable? | Yes, Jiangsu Nhwa is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
